

25 July 2025

Endometrial Cancer

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Yes

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli) <5
- Dostarlimab (Jemperli) AND Chemotherapy <5
- Hormone therapy (Progesterone or Letrozole) <5
- Pembrolizumab (Keytruda) monotherapy <5
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda) 6
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 22
- Any other SACT Paclitaxel <5
- Any other Chemotherapy as above
- Durvalumab with platinum-based chemotherapy <5
- Pembrolizumab with platinum-based chemotherapy <5

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

This information is not available

Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) AND Chemotherapy <5
- Durvalumab with platinum-based chemotherapy <5
- Pembrolizumab with platinum-based chemotherapy <5
- Hormone therapy (Progesterone or Letrozole) <5
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 11
- Any other SACT 6 – Paclitaxel <5, Lenvatinib+Pembro <5



25 July 2025

- **Any other chemotherapy as above**

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?

Unfortunately we do not have any trials in endometrial cancer open at present nor in set -up.